 |
54 Diseases |  |
8 Trials |
|
8 Trials |  |
2662 News |  |
| «12...12131415161718192021222324» |
- | ledipasvir/sofosbuvir / Generic mfg.
New P4 trial: DAA in the Risk of Recurrence After Curative Treatment of HCC (clinicaltrials.gov) - Nov 8, 2016
P4, N=130, Not yet recruiting, Sponsor: Taipei Veterans General Hospital, Taiwan
- ledipasvir/sofosbuvir / Generic mfg.
Trial primary completion date: Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia (clinicaltrials.gov) - Nov 2, 2016
P4, N=1000, Active, not recruiting, Sponsor: National Institutes of Health Clinical Center (CC)
Trial primary completion date: Jun 2017 --> Jun 2016
- | ledipasvir/sofosbuvir / Generic mfg.
Enrollment open, HEOR: Effects of Harvoni in Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection (clinicaltrials.gov) - Nov 2, 2016
P3, N=30, Enrolling by invitation, Sponsor: University Health Network, Toronto
Trial primary completion date: Jun 2017 --> Jun 2016 Not yet recruiting --> Enrolling by invitation
- ||| ledipasvir/sofosbuvir / Generic mfg.
New trial: Harvoni in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea (clinicaltrials.gov) - Nov 1, 2016
P=N/A, N=3000, Not yet recruiting, Sponsor: Gilead Sciences
- ledipasvir/sofosbuvir / Generic mfg.
Enrollment closed: Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia (clinicaltrials.gov) - Oct 31, 2016
P4, N=1000, Active, not recruiting, Sponsor: National Institutes of Health Clinical Center (CC)
Not yet recruiting --> Enrolling by invitation Enrolling by invitation --> Active, not recruiting
- ledipasvir/sofosbuvir / Generic mfg.
Enrollment open, Trial initiation date, Trial primary completion date: Determine the Efficacy and Safety of Harvoni in Genotype 1 Chronic Hepatitis c Infected People Who Are Alcoholics (clinicaltrials.gov) - Oct 28, 2016
P4, N=30, Recruiting, Sponsor: University of Nebraska
Enrolling by invitation --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: May 2016 --> Aug 2016 | Trial primary completion date: May 2017 --> Aug 2017
- ledipasvir/sofosbuvir / Generic mfg.
Trial primary completion date: Effect of Harvoni on Proteinuria and eGFR in Hepatitis C Virus Associated Chronic Kidney Disease (CKD) (clinicaltrials.gov) - Oct 25, 2016
P=N/A, N=24, Recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting | Initiation date: May 2016 --> Aug 2016 | Trial primary completion date: May 2017 --> Aug 2017 Trial primary completion date: Dec 2016 --> Apr 2017
- | Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment open, Trial primary completion date: CTN289: HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection (clinicaltrials.gov) - Oct 20, 2016
P3, N=25, Recruiting, Sponsor: Ottawa Hospital Research Institute
Trial primary completion date: Dec 2016 --> Apr 2017 Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2017 --> Jul 2017
- |||| ledipasvir/sofosbuvir / Generic mfg.
Trial completion, Trial primary completion date: Comparative Efficacy of Fixed-dose Combination Sofosbuvir + Ledipasvir, 8 vs. 12 Weeks in Chronic Hepatitis C Genotype 6 (clinicaltrials.gov) - Oct 14, 2016
P4, N=60, Completed, Sponsor: Stanford University
Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2017 --> Jul 2017 Recruiting --> Completed | Trial primary completion date: Apr 2017 --> Oct 2016
- || ledipasvir/sofosbuvir / Generic mfg.
Trial primary completion date: Use-Results Surveillance Study of Harvoni (clinicaltrials.gov) - Oct 11, 2016
P=N/A, N=3000, Recruiting, Sponsor: Gilead Sciences
Recruiting --> Completed | Trial primary completion date: Apr 2017 --> Oct 2016 Trial primary completion date: Jul 2018 --> Sep 2017
- ledipasvir/sofosbuvir / Generic mfg.
Enrollment closed, IO biomarker: Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs (clinicaltrials.gov) - Oct 6, 2016
P4, N=36, Active, not recruiting, Sponsor: Rockefeller University
Trial primary completion date: Jul 2018 --> Sep 2017 Recruiting --> Active, not recruiting
- ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Trial primary completion date: Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency (clinicaltrials.gov) - Sep 16, 2016
P2b, N=35, Recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2017 --> Jun 2017
- | ledipasvir/sofosbuvir / Generic mfg.
Enrollment open: Egypt Peds: Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy (clinicaltrials.gov) - Sep 14, 2016
P2, N=40, Recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Feb 2017 --> Jun 2017 Not yet recruiting --> Recruiting
- ||||| ledipasvir/sofosbuvir / Generic mfg.
Enrollment closed: Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection (clinicaltrials.gov) - Sep 14, 2016
P3b, N=239, Active, not recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ledipasvir/sofosbuvir / Generic mfg.
Enrollment open: Study of Hepatitis C Treatment During Pregnancy (clinicaltrials.gov) - Sep 7, 2016
P1, N=15, Recruiting, Sponsor: University of Pittsburgh
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || ledipasvir/sofosbuvir / Generic mfg.
Trial primary completion date: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection (clinicaltrials.gov) - Sep 6, 2016
P2, N=200, Recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2017 --> Jan 2018
- Pegasys (pegylated interferon ? -2a) / Roche, Sunvepra (asunaprevir) / BMS, Olysio (simeprevir) / J&J, Medivir
Trial primary completion date: SWITCH-1: Switching Regimen in Treating Cirrhotic HCV GT1b Subjects (clinicaltrials.gov) - Aug 22, 2016
P2, N=160, Recruiting, Sponsor: Humanity & Healthy GI and Liver Centre
Trial primary completion date: Jul 2017 --> Jan 2018 Trial primary completion date: Sep 2016 --> Dec 2016
- Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) / AbbVie, Enanta Pharma, Exviera (dasabuvir) / AbbVie
Trial primary completion date: DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO) (clinicaltrials.gov) - Aug 22, 2016
P2/3, N=32, Recruiting, Sponsor: Humanity & Healthy GI and Liver Centre
Trial primary completion date: Sep 2016 --> Dec 2016 Trial primary completion date: Jun 2016 --> Jun 2017
- Daklinza (daclatasvir) / BMS
Trial primary completion date: Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT2 Infected Patients (clinicaltrials.gov) - Aug 22, 2016
P4, N=120, Recruiting, Sponsor: Humanity & Healthy GI and Liver Centre
Trial primary completion date: Jun 2016 --> Jun 2017 Trial primary completion date: Jun 2016 --> Dec 2016
- ledipasvir/sofosbuvir / Generic mfg.
Enrollment open, Trial initiation date, Trial primary completion date: STOP-CO: Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant (clinicaltrials.gov) - Aug 19, 2016
P4, N=50, Recruiting, Sponsor: University of California, San Francisco
Trial primary completion date: Jun 2016 --> Dec 2016 Not yet recruiting --> Recruiting | Initiation date: Oct 2015 --> Aug 2016 | Trial primary completion date: Dec 2017 --> Dec 2018
- | ledipasvir/sofosbuvir / Generic mfg.
New P2 trial: Egypt Peds: Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy (clinicaltrials.gov) - Aug 15, 2016
P2, N=40, Not yet recruiting, Sponsor: Gilead Sciences
- || Zepatier (grazoprevir/elbasvir) / Merck (MSD), Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) / AbbVie, Enanta Pharma, Exviera (dasabuvir) / AbbVie
Trial primary completion date: PRIORITIZE: Study of Oral Treatments for Hepatitis C (clinicaltrials.gov) - Aug 11, 2016
P4, N=3750, Recruiting, Sponsor: University of Florida
Not yet recruiting --> Recruiting | Initiation date: Oct 2015 --> Aug 2016 | Trial primary completion date: Dec 2017 --> Dec 2018 Trial primary completion date: Feb 2021 --> Aug 2020
- | ledipasvir/sofosbuvir / Generic mfg.
New P4 trial, Metastases: Hepatitis C Virus(HCV) Heart and Lung Study (clinicaltrials.gov) - Aug 8, 2016
P4, N=50, Not yet recruiting, Sponsor: Duke University
- ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Phase classification: Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency (clinicaltrials.gov) - Aug 3, 2016
P2b, N=35, Recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Feb 2021 --> Aug 2020 Phase classification: P2 --> P2b
- ||||| ledipasvir/sofosbuvir / Generic mfg.
Enrollment closed: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection (clinicaltrials.gov) - Aug 3, 2016
P3b, N=111, Active, not recruiting, Sponsor: Gilead Sciences
Phase classification: P2 --> P2b Recruiting --> Active, not recruiting
- |||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) / J&J, Gilead
Trial primary completion date: Co-STARs: Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment (clinicaltrials.gov) - Aug 2, 2016
P3b, N=240, Recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Trial primary completion date: May 2017 --> Aug 2017
- |||| ledipasvir/sofosbuvir / Generic mfg.
Trial completion: Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection (clinicaltrials.gov) - Jul 19, 2016
P2, N=114, Completed, Sponsor: Gilead Sciences
Trial primary completion date: May 2017 --> Aug 2017 Active, not recruiting --> Completed
- ledipasvir/sofosbuvir / Generic mfg.
Trial primary completion date: Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia (clinicaltrials.gov) - Jul 19, 2016
P4, N=1000, Enrolling by invitation, Sponsor: National Institutes of Health Clinical Center (CC)
Active, not recruiting --> Completed Trial primary completion date: Jun 2016 --> Jun 2017
- ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Trial primary completion date: SWIFT-C: Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection (clinicaltrials.gov) - Jul 19, 2016
P1, N=50, Recruiting, Sponsor: AIDS Clinical Trials Group
Trial primary completion date: Jun 2016 --> Jun 2017 Trial primary completion date: Nov 2016 --> Feb 2017
- ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Trial initiation date: SL50: Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1 (clinicaltrials.gov) - Jul 19, 2016
P3, N=50, Not yet recruiting, Sponsor: Tehran University of Medical Sciences
Trial primary completion date: Nov 2016 --> Feb 2017 Initiation date: Apr 2016 --> Sep 2016
- sofosbuvir/velpatasvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
New P2 trial: BArT: Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection (clinicaltrials.gov) - Jul 19, 2016
P2, N=50, Recruiting, Sponsor: Fondazione Italiana Linfomi ONLUS
- |||||| ledipasvir/sofosbuvir / Generic mfg.
Enrollment open, Phase classification: Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV Infection (clinicaltrials.gov) - Jul 11, 2016
P3b, N=360, Recruiting, Sponsor: Gilead Sciences
Initiation date: Apr 2016 --> Sep 2016 Active, not recruiting --> Recruiting | Phase classification: P3 --> P3b
- | sofosbuvir/velpatasvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
New P2/3 trial: Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia (clinicaltrials.gov) - Jul 7, 2016
P2/3, N=10, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
- ||||||| ledipasvir/sofosbuvir / Generic mfg.
Trial completion, Phase classification: Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection (clinicaltrials.gov) - Jul 7, 2016
P3b, N=153, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Recruiting | Phase classification: P3 --> P3b Active, not recruiting --> Completed | Phase classification: P3 --> P3b
- ||||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Enrollment closed, Phase classification: Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies (clinicaltrials.gov) - Jul 6, 2016
P3b, N=300, Active, not recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed | Phase classification: P3 --> P3b Recruiting --> Active, not recruiting | Phase classification: P3 --> P3b
- || Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead
Trial primary completion date: A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection (clinicaltrials.gov) - Jun 29, 2016
P=N/A, N=2000, Enrolling by invitation, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting | Phase classification: P3 --> P3b Trial primary completion date: Mar 2021 --> Nov 2022
- |||| Zepatier (grazoprevir/elbasvir) / Merck (MSD), Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) / AbbVie, Enanta Pharma, Exviera (dasabuvir) / AbbVie
Enrollment open: PRIORITIZE: Study of Oral Treatments for Hepatitis C (clinicaltrials.gov) - Jun 24, 2016
P4, N=3750, Recruiting, Sponsor: University of North Carolina, Chapel Hill
Trial primary completion date: Mar 2021 --> Nov 2022 Not yet recruiting --> Recruiting
- || ledipasvir/sofosbuvir / Generic mfg.
Phase classification: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection (clinicaltrials.gov) - Jun 24, 2016
P3b, N=100, Recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Phase classification: P3 --> P3b
- ||||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Enrollment closed: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection (clinicaltrials.gov) - Jun 20, 2016
P3, N=255, Active, not recruiting, Sponsor: Gilead Sciences
Phase classification: P3 --> P3b Recruiting --> Active, not recruiting
- || Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) / J&J, Gilead
Phase classification: Co-STARs: Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment (clinicaltrials.gov) - Jun 9, 2016
P3b, N=240, Recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Phase classification: P3 --> P3b
- ledipasvir/sofosbuvir / Generic mfg.
Enrollment open: LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients (clinicaltrials.gov) - Jun 9, 2016
P4, N=230, Recruiting, Sponsor: Medical University of South Carolina
Phase classification: P3 --> P3b Not yet recruiting --> Recruiting
- || ledipasvir/sofosbuvir / Generic mfg.
Phase classification: Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection (clinicaltrials.gov) - Jun 2, 2016
P3b, N=225, Recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Phase classification: P3 --> P3b
- ledipasvir/sofosbuvir / Generic mfg.
Trial initiation date, Trial primary completion date: Study of Hepatitis C Treatment During Pregnancy (clinicaltrials.gov) - Jun 1, 2016
P1, N=15, Not yet recruiting, Sponsor: University of Pittsburgh
Phase classification: P3 --> P3b Initiation date: Apr 2016 --> Jul 2016 | Trial primary completion date: Apr 2018 --> Jul 2018
- ||||| Zepatier (grazoprevir/elbasvir) / Merck (MSD), Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) / AbbVie, Enanta Pharma, Exviera (dasabuvir) / AbbVie
New P4 trial: PRIORITIZE: Study of Oral Treatments for Hepatitis C (clinicaltrials.gov) - Jun 1, 2016
P4, N=3750, Not yet recruiting, Sponsor: University of North Carolina, Chapel Hill
- | Olysio (simeprevir) / J&J, Medivir
Trial completion: A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection (clinicaltrials.gov) - May 31, 2016
P2, N=41, Completed, Sponsor: Janssen Sciences Ireland UC
Initiation date: Apr 2016 --> Jul 2016 | Trial primary completion date: Apr 2018 --> Jul 2018 Recruiting --> Completed
- |||||| ledipasvir/sofosbuvir / Generic mfg.
Enrollment open: Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection (clinicaltrials.gov) - May 13, 2016
P3, N=225, Recruiting, Sponsor: Gilead Sciences
Recruiting --> Completed Not yet recruiting --> Recruiting
- |||| voxilaprevir (GS-9857) / Gilead
Trial completion: LEPTON: Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection (clinicaltrials.gov) - May 13, 2016
P2, N=269, Completed, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || Olysio (simeprevir) / J&J, Medivir, Daklinza (daclatasvir) / BMS
New P3 trial: FRI-STC: Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC (clinicaltrials.gov) - May 13, 2016
P3, N=150, Recruiting, Sponsor: National Hepatology & Tropical Medicine Research Institute
- | ledipasvir/sofosbuvir / Generic mfg.
New P4 trial: Program of Screening, Prevention and Elimination of Hepatitis C in Penitentiary Institutions in Cantabria (JAILFREE-C) (clinicaltrials.gov) - May 11, 2016
P4, N=120, Recruiting, Sponsor: Instituto de Investigaci
- |||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Trial primary completion date: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection (clinicaltrials.gov) - May 9, 2016
P3, N=280, Recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Trial primary completion date: Sep 2016 --> Dec 2016